Acute renal failure/ fluid overload Urological and Genital Diseases Acute renal failure
Conditions
Interventions
The same dialysis membrane, AN69ST, will be used for both the intervention and control treatment. Two different heparinization strategies will be compared:
Control group (usual heparin doses): Bolus
Sponsors
Gambro Lundia AB (Sweden)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients requiring continuous renal replacement therapies (CRRT) 2. Aged 18 and over 3. Patients weighing 30-120 kg 4. Patients having signed a written consent to participate in the study
Exclusion criteria
Exclusion criteria: 1. History of heparin antibodies or heparin-induces thrombocytopenia 2. Known hypertensive to any dialysis membrane 3. Current enrolment in another trial which could impact the successful completion of this study 4. Patients under guardianship 5. Patient anticipated to require transportation outside the unit for diagnostic or therapeutic procedures in the coming first week .These patients can eventually be included in a later more stable phase 6. Unconscious patients for whom no relative or person of trust can give consent to treatment. In the absence of any relative or person of trust, the patient in question cannot be included in the study 7. Patient requiring anticoagulation for other indications e.g., valvular surgery or extracorporeal ventricular assist devices 8. Patients with active bleeding who does not require heparinization
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Filter lifespan, defined as the time period between patient's connection and filter disconnection due to filter clotting. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events, monitored for up to 24 days of treatment | — |
Countries
Sweden
Outcome results
None listed